Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 1.29 CAD 0.78% Market Closed
Market Cap: 373m CAD

Spectral Medical Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Spectral Medical Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Stock-Based Compensation
CA$2.1m
CAGR 3-Years
22%
CAGR 5-Years
19%
CAGR 10-Years
20%
Theratechnologies Inc
TSX:TH
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Stock-Based Compensation
$12.4m
CAGR 3-Years
-12%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Stock-Based Compensation
$16.9m
CAGR 3-Years
-21%
CAGR 5-Years
4%
CAGR 10-Years
19%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Stock-Based Compensation
$53.2m
CAGR 3-Years
45%
CAGR 5-Years
58%
CAGR 10-Years
31%
Willow Biosciences Inc
TSX:WLLW
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
373m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
1 CAD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Spectral Medical Inc's Stock-Based Compensation?
Stock-Based Compensation
2.1m CAD

Based on the financial report for Sep 30, 2025, Spectral Medical Inc's Stock-Based Compensation amounts to 2.1m CAD.

What is Spectral Medical Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
20%

Over the last year, the Stock-Based Compensation growth was 24%. The average annual Stock-Based Compensation growth rates for Spectral Medical Inc have been 22% over the past three years , 19% over the past five years , and 20% over the past ten years .

Back to Top